Literature DB >> 15221936

mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma.

Kathrin Katenkamp1, Alexander Berndt, Winfried Hindermann, Heiko Wunderlich, Karl Michael Haas, Laura Borsi, Luciano Zardi, Hartwig Kosmehl.   

Abstract

The inclusion or omission of the alternatively spliced region in the tenascin-C (Tn-C) mRNA gives rise to the large (Tn-C(L)) or small (Tn-C(S)) variant, respectively. Tn-C(L) is thought to be a typical component of provisional extracellular matrices (ECMs) and is expressed during tumour stroma remodelling in cancer. Tn-C(L) mRNA expression and protein distribution have been studied in 44 prostatic adenocarcinomas using RNA/RNA in situ hybridization supplemented by reverse transcriptase-polymerase chain reaction (RT-PCR), and immunohistochemistry (clone BC-2). While the Tn-C(L) protein was demonstrated within tumour stroma, Tn-C(L) mRNA expression was mainly observed in carcinoma cells, regardless of the histological grade of the tumour. Carcinoma cells containing Tn-C(L) mRNA were particularly localized at the tumour invasion front. Tn-C(L) mRNA was also identified in benign prostatic hyperplasia, where it was present exclusively in the basal cell layer, and in prostatic intraepithelial neoplasia in which there was partial loss of positive basal cells and increasing positivity of luminal cells. Furthermore, newly formed tumour blood vessels and inflammatory and stromal cells take part in the expression of Tn-C(L) and are involved in the formation of a provisional tumour matrix. It is concluded that deposits of Tn-C(L) indicate rebuilding processes in non-neoplastic as well as in neoplastic prostatic tissues. In respect of the Tn-C(L) synthesis in budding prostatic carcinoma cells, the results demonstrate that tumour cells can directly produce the ECM components of carcinoma stroma, creating conditions that facilitate the process of invasion. Copyright 2004 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221936     DOI: 10.1002/path.1589

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  12 in total

1.  High-molecular tenascin-C as an indicator of atypical cells in oral brush biopsies.

Authors:  O Driemel; R Dahse; A Berndt; H Pistner; S G Hakim; L Zardi; T E Reichert; H Kosmehl
Journal:  Clin Oral Investig       Date:  2006-11-17       Impact factor: 3.573

2.  Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?

Authors:  Falk Ohl; Monika Jung; Chuanliang Xu; Carsten Stephan; Anja Rabien; Mick Burkhardt; Andreas Nitsche; Glen Kristiansen; Stefan A Loening; Aleksandar Radonić; Klaus Jung
Journal:  J Mol Med (Berl)       Date:  2005-10-07       Impact factor: 4.599

Review 3.  Insights into the nuclear export of murine leukemia virus intron-containing RNA.

Authors:  Lucie Pessel-Vivares; Laurent Houzet; Sébastien Lainé; Marylène Mougel
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

4.  The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.

Authors:  Chiara Catania; Michela Maur; Rossana Berardi; Andrea Rocca; Anna Maria Di Giacomo; Gianluca Spitaleri; Cristina Masini; Chiara Pierantoni; Reinerio González-Iglesias; Giulia Zigon; Annaelisa Tasciotti; Leonardo Giovannoni; Valeria Lovato; Giuliano Elia; Hans D Menssen; Dario Neri; Stefano Cascinu; Pier Franco Conte; Filippo de Braud
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

5.  Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.

Authors:  Alexander Berndt; Katharina Anger; Petra Richter; Laura Borsi; Simon Brack; Michela Silacci; Marcus Franz; Heiko Wunderlich; Mieczyslaw Gajda; Luciano Zardi; Dario Neri; Hartwig Kosmehl
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-31       Impact factor: 4.553

6.  [Clinical and immunohistochemical findings of intra- and extraoral angiosarcomas].

Authors:  Oliver Driemel; A Berndt; A Hartmann; U D Mueller-Richter; R Bauer; T E Reichert; H Kosmehl
Journal:  Mund Kiefer Gesichtschir       Date:  2006-07

7.  A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies.

Authors:  Alexander Berndt; Robert Köllner; Petra Richter; Marcus Franz; Astrid Voigt; Angela Berndt; Laura Borsi; Raffaella Giavazzi; Dario Neri; Hartwig Kosmehl
Journal:  Histochem Cell Biol       Date:  2010-03-17       Impact factor: 4.304

Review 8.  Tenascin-C and carcinoma cell invasion in oral and urinary bladder cancer.

Authors:  Alexander Berndt; Petra Richter; Hartwig Kosmehl; Marcus Franz
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

9.  B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?

Authors:  Petra Richter; Markus Tost; Marcus Franz; Annelore Altendorf-Hofmann; Kerstin Junker; Laura Borsi; Dario Neri; Hartwig Kosmehl; Heiko Wunderlich; Alexander Berndt
Journal:  J Cancer Res Clin Oncol       Date:  2009-03-27       Impact factor: 4.553

10.  Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms.

Authors:  Rachael A Hancox; Michael D Allen; Deborah L Holliday; Dylan R Edwards; Caroline J Pennington; David S Guttery; Jacqueline A Shaw; Rosemary A Walker; J Howard Pringle; J Louise Jones
Journal:  Breast Cancer Res       Date:  2009-04-30       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.